Peninsula Pharmaceuticals and Shionogi & Co., to collaborate on doripenem

Published: 28-May-2003

California-based Peninsula Pharmaceuticals and Japanese company Shionogi & Co., of Osaka, have reached a licensing agreement for doripenem (S-4661), a broad-spectrum antibiotic currently being studied in worldwide clinical trials.


California-based Peninsula Pharmaceuticals and Japanese company Shionogi & Co., of Osaka, have reached a licensing agreement for doripenem (S-4661), a broad-spectrum antibiotic currently being studied in worldwide clinical trials.

Peninsula has obtained exclusive rights to develop and market doripenem in North America; Shionogi will manufacture the product for worldwide distribution.

Doripenem, is the newest member of the carbapenem class of antibacterials and displays broad in vitro potency against aerobic, anaerobic, gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa, Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae (PRSP). The worldwide hospital antibacterial market exceeds US$8bn annually and the worldwide market for carbapenems is close to $1.0bn and growing. By 2006, the carbapenem market is expected to grow by 50%.

'We feel our highly focused approach to development will help take doripenem further into the clinic and ultimately, the market,' said Paul F. Truex, president, Peninsula Pharmaceuticals. 'Shionogi has developed a cutting-edge strategy for seeking the best worldwide development options for their novel pharmaceutical products.'

You may also like